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Abstract
Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based
on multiple guidelines. However, ethnic differences with respect to thrombogenicity have been reported and the incidence
of thromboembolic events is considered to be lower in the Asian population. Despite the importance of thromboprophylaxis, bleeding is also a side effect that should be considered. We examine the data relating to potential ethnic differences
in thrombosis and bleeding in COVID-19. Although sufficient data is not yet available, current evidence does not oppose
routine anticoagulant use and thromboprophylaxis using a standard dose of LMWH for admitted patients regardless of
ethnicity based on our review.
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Introduction
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic has posed a significant impact on
morbidity and mortality in hospitalized patients. However,
the incidence of death varies among different ethnic groups,
as a New York state report notes that per-population coronavirus disease 2019 (COVID-19) fatality rates were 0.03%,
0.18%, and 0.12% for Caucasian, African-American, and
Hispanic populations, respectively, and 5.38-fold disparity
for African-American relative to Caucasian communities
was observed [1]. The cause of ethnic disparities in mortality

includes presence of other disease status such as hypertension, diabetes, however, different risks for thromboembolism
among populations can be involved [2]. Apart from COVID19, a survey performed in the USA reported the prevalence
of venous thromboembolism (VTE) per 100,000 population
was highest in African-American, followed by Caucasian,
Hispanic, and other populations (Asians/Pacific Islanders)
[3]. Thus, is the incidence of death and thrombotic complications among Asian COVID-19 patients lower than the other
ethnicities? Although the clinical data regarding the thrombotic complications in the Asian population is still scarce,
the question of whether the standard thromboprophylaxis
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is necessary to be applied equally to all populations should
be considered. In this review, we examined the data about
the inter-ethnic difference of thrombosis in COVID-19 and
discuss the validity of universal thromboprophylaxis.

The ethnic difference on mortality
in COVID‑19
The death toll of COVID-19 reached 350,000 in August
2020 and roughly half was recorded in Europe and followed
by North America. The count changes depending on the timing of disease spread but it still less than 10,000 deaths in
South-East Asia and Western Pacific (https://covid19.who.
int accessed Aug 8, 2020). The mortality difference in
COVID-19 has been reported and the National Health Service (NHS) data of the United Kingdom revealed that Black
and Asian groups are at increased risk of infection and death
from COVID-19. The age and region adjusted NIH data suggested a lower risk of death for White Irish and White British
ethnic groups, but increased risk of death for Black African
(3.24, 95% confidence interval [CI] 2.90–3.62), Indian (1.70,
95% CI 1.56–1.85), and other minor ethnic populations [4].
Another study also from the UK that utilized more than
10,000 COVID-19-related death records demonstrated that
age‐sex adjusted hospital death rates for Black COVID‐19
patients are 2.17‐times higher compared to those in White,
and 1.95-times higher than Asian patients [5]. A similar
but larger survey was performed in Brazil. Baqui et al. [6]
performed a cross-sectional study on 11,321 patients and
reported, Pardo (mixed ethnicity) and Black Brazilian ethnicity with COVID-19 had a higher risk of mortality (hazard
ratio [HR] 1.45, 95% CI 1.33–1.58 for Pardo; HR 1.32, 95%
CI 1.15–1.52 for Black Brazilians) compared with White
Brazilians. However, the association between the Black race
and increased mortality is still uncertain because the elimination of factors regarding inequity in health, health care
access, and quality of care is not easy [7]. Price-Haywood
[8] collected the data from 3481 COVID-19 patients from
the integrated-delivery health system in Louisiana, USA
and demonstrated that race, increasing age, a higher score
on the comorbidity index, public insurance (Medicare or
Medicaid), residence in a low-income area, and obesity were
associated with increased odds of hospital admission. On the
other hand, in adjusted time-to-event analyses, variables that
were associated with higher in-hospital mortality were old
age and elevated respiratory rate at presentation, elevated
lactate levels, creatinine, or procalcitonin, or low platelet or
lymphocyte counts, and Black race was not associated with
higher mortality. A similar result was also reported from
Ohio, USA [9]. Thus, the relationship between ethnicity and
disease severity or death still remains to be clarified.
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The ethnic disparities of deep vein
thrombosis and thromboembolism
Even before the COVID-19 pandemic, the prevalence of
VTE was high in the United States and reported to be 100
per 100,000 persons each year. Approximately one-third
of patients with symptomatic VTE manifest pulmonary
embolism (PE), whereas two-thirds manifest deep vein
thrombosis (DVT) alone [10]. The prevalence of thromboembolism differs considerably among different ethnic
and population groups, and it is significantly higher in
African Americans and Caucasians compared to Hispanic
and Asian-Pacific Islanders [11]. In Japanese, the incidence of VTE is reportedly approximately one-eighth of
North Americans [12, 13]. Factor V Leiden mutation,
deficiencies of protein C, protein S, and antithrombin are
the assumed hereditary relevant factors. Hyperhomocysteinemia and elevated levels of factors I, VIII and XI, are
the other possible hereditary risk factors [14]. However,
the difference may not be arisen from the ethnic difference
but due to the lack of well-designed studies as well as nonstandardized survey designs [15]. As a matter of fact, the
incidence of VTE in Asian countries has risen recently and
doubled in the past 10 years [12, 13]. This could be attributed to lifestyle changes, ageing population, increasing
awareness of VTE [15]. For the comparison of the interracial incidence, it is difficult to control lifestyle factors
such as diet or exercise, and eliminate the environmental
factors, but Nicole Tran et al. [16] examined more than
60,000 residents in northern California demonstrated the
adjusted HR for VTE in Asian ethnic was 0.5 to the Caucasians (Chinese 0.5, Japanese 0.5, Filipino 0.6, and South
Asian 0.9). In addition, a population-based study examined
the risk of postpartum VTE in the US reported African
American and Asian women had a greater and lower risk
of VTE compared to the Caucasian women (adjusted odds
ratio [OR] 1.50 and 0.67, respectively) [17]. After all, the
ethnic difference in VTE incidence still remains unclear,
but it could be lower in the Asian countries compared to
than Western countries [18, 19].

Thrombosis in COVID‑19 and ethnic
differences
Thromboembolic events in COVID-19 is a major concern for clinicians. Santoliquido et al. [20] performed
a systematic screening of lower limb vein by compression ultrasonography in non-ICU hospitalized COVID-19
patients and reported the incidence of DVT was 11.9%.
However, the incidence considerably varies among the
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reports and the prevalence of VTE ranges from 3 to 85%
[21]. The wide range of this incidence probably arisen
from the diversity in study design (systematic or selected
screening), setting (ICU vs general wards), intervention
(uniform or individual thromboprophylaxis), and timing of the examination. Therefore, inter-race differences
should be examined in a similar condition. In the ICU setting, a French study examined critically ill patients using
complete duplex ultrasound and reported the overall VTE
rate of 69% [22]. Another study also performed in France
reported a DVT rate of 65% at admission, and 79% at 48 h
after ICU admission [23]. As for the Asian ethnicity, a Chinese study performed in COVID-19 ICU patients reported
46–85.4% incidence of DVT [24] (Table 1). Although the
studies performed in ICU generally include only a small
number of cases, the incidence of DVT in Chinese patients
does not seem to be lower than that of Caucasians. However, we should be careful about translating these results
since many of the ICU patients are sedated and the patients

do not complain the symptom appropriately. Therefore, the
routine screening is recommended in this setting.

Mechanism of thrombus formation
in COVID‑19
Understanding the pathophysiology of COVID-19-associated coagulopathy is important to assess the necessity of
thromboprophylaxis. However, the underlying mechanisms
are multifactorial [31, 32]. Recent studies emphasize the
importance of the endothelial injury caused by SARS-CoV-2
infection leading to micro- and macrothrombosis in COVID19 [33]. The relative significance of DVT/PE in the development of respiratory failure or critical illness may be decreasing based on recent reports [34]. The endotheliopathy of
COVID-19 causes vascular endothelial dysfunction, loss
of its anticoagulant properties, and is associated with other
factors contributing to the hypercoagulability that include

Table 1  The incidence of deep vein thrombosis in ICU patients detected by ultrasonography reported from Asia and Europe
Country

Patient/setting

Number Measure

Timing of assessment

DVT prophylaxis

China [24]

Patients in ICU

48

Compression ultrasonography

Not assessed

China [25]

Critically ill patients 88
in ICU

Compression ultrasonography

China [26]

Critically ill patients 143
managed by intensivists

Ultrasonography
scanning

France [22]

Patients in ICU

26

Duplex ultrasonography

France [23]

Patients with ARDS 34
and treated in ICU

Duplex ultrasonography

Standard LMWH
thromboprophylaxis
Standard LMWH
More than 1 week
thromboprophyafter ICU admislaxis
sion
Not assessed
37.1% Received
standard LMWH
and others no
thromboprophylaxis
Day 1–7 after
Standard or
admission
therapeutic dose of
LMWH or unfractionated heparin
48 h after admission Standard thromboprophylaxis

Switzerland [27]

Critically ill patients 25
in ICU

Ultrasonography
screening

Day 5–10 after
admission

The Netherlands
[28]

Patients in ICU

75

Ultrasonography
screening

Day 7–21 after
admission

The Netherlands
[29]

Patients in ICU

184

Ultrasonography
screening

During ICU stay

Standard or higher
dose thromboprophylaxis

Italy [30]

Patients in ICU

61

Compression ultrasonography

During ICU stay

Standard or
therapeutic dose of
LMWH

Continuous
intravenous infusion of heparin
(15,000 IU/24 h)
Standard to double
dose of LMWH

Incidence of DVT
DVT; 85.4%
Proximal DVT; 75%
Distal DVT; 10.4%
DVT; 46%
Proximal DVT; 9.1%
Distal DVT; 46%
DVT 46.1%
Proximal DVT; 16.1%
Distal DVT; 30.1%
DVT; 69%
Proximal DVT; 26%
Distal DVT; 68%
DVT 79%
Proximal DVT; 16.1%
Distal DVT; 30.1%
DVT/VTE; 32%
proximal DVT; 24%
pulmonary embolism;
20%
DVT Day7; 26%, Day
14; 47%, Day 21;
59%
Thrombosis 31%
(VTE in 27%,
arterial thrombosis
3.7%)
Thrombosis 27.6%

DVT deep vein thrombosis, VTE venous thromboembolism, LMWH low-molecular-weight heparin
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increased release of von Willebrand factor (VWF), Factor
VIII, and angiopoietin 2, increased fibrinogen, presence
of antiphospholipid antibodies, and dysregulated inflammation. As a result, the loss of endothelial function along
with a marked systemic hypercoagulability is estimated to
be the major cause of pulmonary microthrombotic injury
and respiratory failure [35]. It is noteworthy that African‐
Americans are reported to have higher circulating levels of
VWF, Factor VIII and fibrinogen [36]. The differences in
endothelial function and molecular mechanisms of thrombosis risk due to genetic factors may lead to the ethnic disparities in COVID-19-associated thrombosis [37]. With respect
to the comparison of endothelial dysfunction in Asians and
other ethnicities, little data are available to make any conclusions. Investigations as to the levels of VWF, Factor VIII,
and fibrinogen in response to infection in various races are
expected to provide the data that clarify the ethnic disparity
of COVID‐19-associated thrombosis.

Thromboprophylaxis in COVID‑19
There are two aims for thromboprophylaxis in COVID-19,
suppression of microthrombus formation and prevention of
macrothrombosis. The International Society on Thrombosis
and Haemostasis (ISTH) released guidelines for thromboprophylaxis in COVID-19 and recommend universal standard prophylaxis using LMWH unless contraindication for
all hospitalized patients [38]. Following this recommendation, other international organization such as World Health
Organization (WHO) propose a similar recommendation
[39]. Although thromboprophylaxis is effective, the incidence is still high with standard prophylaxis and more intensive prophylaxis is expected. However, the bleeding adverse
event is a serious problem and the net effect of prophylaxis
with higher dose is still unknown [40]. ISTH recommendations are conservative for a more aggressive thromboprophylaxis, and only 30% of experts agreed on the use of
intermediate-dose of LMWH in hospitalized COVID-19
patients, compared to 50% of experts for intermediate-dose
LMWH for the high-risk ICU patients [41]. A recent small
but prospective study reported the efficacy of higher intensity regimen in critically ill patients and the application of
this type of prophylaxis needs to be determined in ongoing
randomized trials [42].
Anticoagulation to reverse organ dysfunction in COVID19 may be different, although its efficacy is unknown.
Russo et al. [43] analyzed the data from 192 consecutive
Italian patients who underwent pre-admission antithrombotic therapy and reported that adjusted regression analyses showed no difference in ARDS on admission, or death
during hospitalization between patients treated with antiplatelets or anticoagulants. This observation suggests that
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thromboprophylaxis does not have sufficient effects on
microthrombosis prevention and protective effect in the progression of COVID-19. In contrast, another observational
study from the USA revealed a better outcome in patients
treated with anticoagulation compared to the patients treated
without anticoagulation. The in-hospital mortality in the
patients who required mechanical ventilation and treated
with anticoagulation was 29.1%, while that of the patients
treated without anticoagulants was 62.7% [44]. This difference may not be achieved only from VTE prevention but
also from the effect of maintenance of microcirculation.
With respect to the bleeding adverse events, the incidence
of major bleeding was 1.9% in the patients treated without
anticoagulants and 3% in those who received anticoagulants
(P = 0.2) [44]. A Chinese study also reported a better prognosis in severe cases with coagulopathy or with markedly
elevated D-dimer [45]. The effects of anticoagulation on
endothelial damage and microcirculation are the topics of
future study.

Bleeding adverse events with pharmacologic
thromboprophylaxis
Based on initial reports, the incidence of bleeding has been
considered to be low in COVID-19 supporting the concept
of potentially higher dose pharmacological thromboprophylaxis. However, since Asian people are estimated to be more
susceptible to anticoagulation compared to the other ethnicities, the application of universal thromboprophylaxis may
pose increased risk for Asian populations. Thus, comparing the bleeding incidence in COVID-19 among different
populations is challenging. Currently, many of the admitted
patients receive thromboprophylaxis, therefore, it is almost
impossible to divide the bleeding that relates to COVID-19
itself from that relates to the anticoagulation. One previous
large-scale observational study from the USA reported the
incidence of 1.9% in the patients without anticoagulation
and 3.0% in the patients with anticoagulation [46]. Table 2
summarized the incidence of bleeding reported from various
countries, and the incidence in China does not seem to be
higher than that in western countries.
The awareness of different bleeding susceptibility with
anticoagulant therapy has arisen based on the experience
of warfarin. Warfarin requirement is highest in Caucasians,
lower in Hispanics, and lowest in Asians because of the differences in genetic background [50]. It is also known that
the bleeding risk of antiplatelets is also higher in the Asian
population [51]. In contrast, such differences are not seen
with direct oral anticoagulants (DOACs) and the DOACs
are more preferable alternatives for Asian patients [52]. As
for the heparin and LMWH in COVID-19, it is too early to
conclude that there is no ethnic difference in bleeding rates,
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Table 2  The incidence of bleedings in COVID-19 patients
Country

Patient/setting

Number DVT prophylaxis

Incidence of thrombotic
events

Incidence of bleeding events

USA [48]

400

9.5%

4.8% (major bleeding; 2.3%)

USA [44]

Critically ill; 144
Non-critically ill; 256
Hospitalized patients

Not assessed

Without anticoagulation;
1.9%
With anticoagulation; 3.0%

Spain [46]

Patients in non-ICU

156

14.7%

1.9%

China [49]

Hospitalized patients
(critically ill 10.9%)
Critically ill patients in
ICU
Patients in ICU

138

2.9%

4.3%

46%

6%

China [25]
France [47]

Switzerland [27] Critically ill patients in
ICU

2773

88
92
25

Standard LMWH thromboprophylaxis
786 (28%) Received
systemic anticoagulation
(oral, subcutaneous, or
intravenous forms)
Standard LMWH thromboprophylaxis
41 (30.1%) Received standard thromboprophylaxis
Standard LMWH thromboprophylaxis
Standard or therapeutic
dose of LMWH or
unfractionated heparin
Continuous intravenous
infusion of heparin
(15,000 IU/24 h)

40% (venous; 79%, arterial 21% (deep muscle; 23%,
21%)
gastro-intestinal 14%,
intracranial; 9%)
DVT/VTE; 32%
Major bleeding; 0%
Minor bleeding; 8%

DVT deep vein thrombosis, VTE venous thromboembolism, LMWH low-molecular-weight heparin

but the present data does not seem to support the idea that
the Asians are more likely to bleed than Caucasians and
other ethnics.

Recommendation
of the thromboprophylaxis for COVID‑19
in various patient groups
Postoperative anticoagulant therapy was proven to reduce
the risk of VTE and has become routine therapy in Western
countries. In contrast, postoperative thromboprophylaxis has
not been done routinely in many Asian countries [53–55].
Certainly, a similar approach may not be adequate in
COVID-19 because the background of the inter-ethnic risk/
benefits difference of the anticoagulation is still uncertain.
To reduce harm from COVID-19 associated VTE, the ISTH
consequently released the guidance for VTE prevention [38,
41], and collaboratively worked with the WHO to share the
knowledge for global VTE management (https://www.isth.
org/news/517212/A-Systematic-Approach-for-ManagingVenous-Thromboembolism-in-Patients-with-COVID-19.
htm). One of the objects of this projects is highlight the
importance of a systematic approach to VTE prevention,
diagnosis and treatment for patients with COVID-19 worldwide. However, ethnic differences have not been considered
in these approaches.
Other than the effects on VTE prevention, anticoagulants are also expected to provide benefit for the treatment
of microthrombosis. Several studies have investigated the

effect of heparins, especially unfractionated heparin, in
patients with bacterial sepsis-associated DIC. The reported
meta-analyses, showed a trend of reduced 28-day mortality
but also revealed a trend toward increased risk of bleeding.
Again, no racial disparity was examined in these analyses
[56–58]. The net effect of heparin on microthrombosis in
COVID-19 is still unclear and further study in different ethnicities is warranted.

Summary
Important observations include the presence of microthrombosis and microangiopathy in the lung associated with
hemorrhage in COVID-19. These findings significantly contributed to disease severity and death. The endothelial damage and microthrombosis contribute to the typical feature
of diffuse alveolar damage, including hyaline membranes
and fibrin deposition in the alveolus that are present even in
patients who are not in critical condition. The development
of large thrombi and embolization accelerate the respiratory
insufficiency and ultimately to death. Thus, the suppression
of microclot formation and prevention of thromboembolism are required as key benefits of anticoagulant therapy.
Of note are the potential ethnic disparities that can exist
in the thrombogenicity and bleeding risk of COVID-19.
Therapeutic considerations for thromboprophylaxis should
potentially be made separately based on the data constructed
upon individual races although there is at present no data
that support this idea. Rather the current evidence does not
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oppose the same regimen to Asian populations as they are
recommended to Western populations. Future protocols for
thromboprophylaxis should be determined based on the balance between the benefits and the risk of bleeding in various
ethnicities.
Acknowledgements This work was supported in part by a Grant-inAid for Special Research in Subsidies for ordinary expenses of private
schools from The Promotion and Mutual Aid Corporation for Private
Schools of Japan.

Compliance with ethical standards
Conflict of interest Iba T. has received a research grant from Japan
Blood Products Organization and JIMRO. Connors JM. receives personal fees from Bristol-Meyer Squibb, Abbott, Portola, and research
funding to the institution from CSL Behring. Spyropoulos AC. reports
research grants and consulting from Janssen Research & Development
LLC, Bayer, Portola, Boehringer Ingelheim, and the ATLAS group.
Wada H received grants and personal fees from Asahi Kasei Pharma
Corporation and Japan Blood Products Organization. Levy JH serves
on the Steering or Advisory Committees for Instrumentation Laboratories, Merck, Octapharma, and Leading Biosciences.

12.
13.
14.
15.
16.
17.

18.
19.
20.

References
1. Holtgrave DR, Barranco MA, Tesoriero JM, Blog DS, Rosenberg ES. Assessing racial and ethnic disparities using a COVID19 outcomes continuum for New York State. Ann Epidemiol.
2020;48:9–14.
2. Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, MartinLoeches I, Browne P, et al. COVID19 coagulopathy in Caucasian
patients. Br J Haematol. 2020;189(6):1044–9.
3. Deitelzweig SB, Lin J, Johnson BH, Schulman KL. Venous thromboembolism in the US: does race matter? J Thromb Thrombolysis.
2011;31(2):133–8.
4. Aldridge RW, Lewer D, Katikireddi SV, Mathur R, Pathak N,
Burns R, et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res. 2020;5:88.
5. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19
death in 17 million patients. Nature. 2020. https: //doi.org/10.1038/
s41586-020-2521-4.
6. Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic
and regional variations in hospital mortality from COVID-19 in
Brazil: a cross-sectional observational study. Lancet Glob Health.
2020;8(8):e1018–26.
7. Evans MK. Covid’s color line—infectious disease, inequity, and
racial justice. N Engl J Med. 2020;383(5):408–10.
8. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization
and mortality among black patients and white patients with Covid19. N Engl J Med. 2020;382(26):2534–43.
9. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H,
Entz A, et al. Clinical characteristics and morbidity associated
with coronavirus disease 2019 in a series of patients in metropolitan detroit. JAMA Netw Open. 2020;3(6):e2012270.
10. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-8.
11. Shen JJ, Cochran CR, Mazurenko O, Moseley CB, Shan G,
Mukalian R, et al. Racial and insurance status disparities in

13

21.

22.

23.

24.

25.
26.

27.

28.

29.

patient safety indicators among hospitalized patients. Ethn Dis.
2016;26(3):443–52.
Guidelines for diagnosis, treatment and prevention of pulmonary
thromboembolism and deep vein thrombosis (JCS 2017) https
://j-circ.or.jp/old/guideline/pdf/JCS2017_ito_h.pdf
Wang KL, Yap ES, Goto S, Zhang S, Siu CW, Chiang CE. The
diagnosis and treatment of venous thromboembolism in asian
patients. Thromb J. 2018;16:4.
Kearon C. Epidemiology of venous thromboembolism. Semin
Vasc Med. 2001;1(1):7–26.
Liew NC, Chang YH, Choi G, Chu PH, Gao X, Gibbs H, et al.
Asian venous thromboembolism guidelines: prevention of venous
thromboembolism. Int Angiol. 2012;31(6):501–16.
Nicole Tran H, Klatsky AL. Lower risk of venous thromboembolism in multiple Asian ethnic groups. Prev Med Rep.
2019;13:268–9.
Blondon M, Harrington LB, Righini M, Boehlen F, Bounameaux
H, Smith NL. Racial and ethnic differences in the risk of postpartum venous thromboembolism: a population-based, case-control
study. J Thromb Haemost. 2014;12(12):2002–9.
Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism
in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011;9:85–91.
JCS. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009).
Circ J. 2011;75:1258–81.
Santoliquido A, Porfidia A, Nesci A, De Matteis G, Marrone
G, Porceddu E, et al. Incidence of deep vein thrombosis among
non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost. 2020. https: //doi.
org/10.1111/jth.14992.
Marchandot B, Trimaille A, Curtiaud A, Matsushita K, Jesel L,
Morel O. Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic. J Thromb Thrombolysis.
2020;21:1–10.
Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M,
Auvray M, et al. High incidence of venous thromboembolic events
in anticoagulated severe COVID-19 patients. J Thromb Haemost.
2020;18(7):1743–6.
Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J,
Maillet JM, et al. Venous thrombosis among critically ill patients
with coronavirus disease 2019 (COVID-19). JAMA Netw Open.
2020;3(5):e2010478.
Ren B, Yan F, Deng Z, Zhang S, Xiao L, Wu M, et al. Extremely
high incidence of lower extremity deep venous thrombosis
in 48 patients with severe COVID-19 in Wuhan. Circulation.
2020;142(2):181–3.
Chen S, Zhang D, Zheng T, Yu Y, Jiang J. DVT incidence and
risk factors in critically ill patients with COVID-19. J Thromb
Thrombolysis. 2020;30:1–7.
Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, et al. Deep
vein thrombosis in hospitalized patients with COVID-19 in
Wuhan, China: prevalence, risk factors, and outcome. Circulation. 2020;142(2):114–28.
Longchamp A, Longchamp J, Manzocchi-Besson S, Whiting L,
Haller C, Jeanneret S, et al. Venous thromboembolism in critically
Ill patients with COVID-19: Results of a screening study for deep
vein thrombosis. Res Pract Thromb Haemost. 2020;4(5):842–7.
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP,
Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020. https
://doi.org/10.1111/jth.14888.
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res.
2020;191:145–7.

Ethnic differences in thromboprophylaxis for COVID‑19 patients: should they be considered?	
30. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P,
Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital
in Milan Italy. Thromb Res. 2020;191:9–14.
31. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities
and thrombosis in patients with COVID-19. Lancet Haematol.
2020;7(6):e438–40.
32. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M.
The unique characteristics of COVID-19 coagulopathy. Crit Care.
2020;24(1):360.
33. Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel
P, et al. Endotheliopathy in COVID-19-associated coagulopathy:
evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–82.
34. Kollias A, Kyriakoulis KG, Stergiou GS, Syrigos K. Heterogeneity in reporting venous thromboembolic phenotypes in COVID19: methodological issues and clinical implications. Br J Haematol. 2020. https://doi.org/10.1111/bjh.16993.
35. Escher R, Breakey N, Lämmle B. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients.
Thromb Res. 2020;192:174–5.
36. Lutsey PL, Cushman M, Steffen LM, Green D, Barr RG, Herrington D, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost. 2006;4(12):2629–35.
37. Ramasamy R, Milne K, Bell D, Stoneham S, Chevassut T.
Molecular mechanisms for thrombosis risk in Black people:
a role in excess mortality from COVID-19. Br J Haematol.
2020;190(2):e78–80.
38. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al.
ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.
39. Thachil J, Juffermans NP, Ranucci M, Connors JM, Warkentin TE, Ortel TL, et al. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost.
2020;18(9):2138–44.
40. Gavioli EM, Sikorska G, Man A, Rana J, Vider E. Current perspectives of anticoagulation in patients with COVID-19. J Cardiovasc Pharmacol. 2020. https://doi.org/10.1097/FJC.0000000000
000861.
41. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba
T, et al. Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with
COVID-19. J Thromb Haemost. 2020;18(8):1859–65.
42. Taccone FS, Gevenois PA, Peluso L, Pletchette Z, Lheureux O,
Brasseur A, et al. Higher intensity thromboprophylaxis regimens
and pulmonary embolism in critically Ill coronavirus disease 2019
patients. Crit Care Med. 2020;48(11):e1087–90.
43. Russo V, Di Maio M, Attena E, Silverio A, Scudiero F, Celentani
D, et al. Clinical impact of pre-admission antithrombotic therapy
in hospitalized patients with COVID-19: a multicenter observational study. Pharmacol Res. 2020;159:104965.
44. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin
MA, et al. Association of treatment dose anticoagulation with inhospital survival among hospitalized patients with COVID-19. J
Am Coll Cardiol. 2020;76(1):122–4.
45. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost.
2020;18(5):1094–9.

46. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L,
Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, et al.
Incidence of asymptomatic deep vein thrombosis in patients with
COVID-19 pneumonia and elevated D-dimer levels. Thromb Res.
2020;192:23–6.
47. Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou
D. Thrombotic and hemorrhagic events in critically ill COVID19 patients: a French monocenter retrospective study. Crit Care.
2020;24(1):275.
48. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty
AE, Waheed A, et al. COVID-19 and coagulation: bleeding and
thrombotic manifestations of SARS-CoV-2 infection. Blood.
2020;136(4):489–500.
49. Xu JF, Wang L, Zhao L, Li F, Liu J, Zhang L, et al. Risk assessment of venous thromboembolism and bleeding in COVID-19
patients. Res Sqare. 2020. https://doi.org/10.21203/rs.3.rs-18340
/v1.
50. Mak M, Lam C, Pineda SJ, Lou M, Xu LY, Meeks C, et al. Pharmacogenetics of warfarin in a diverse patient population. J Cardiovasc Pharmacol Ther. 2019;24(6):521–33.
51. Hoshino T, Sissani L, Labreuche J, Bousser MG, Chamorro A,
Fisher M, et al. Non-cardioembolic stroke/transient ischaemic
attack in Asians and non-Asians: a post-hoc analysis of the PERFORM study. Eur Stroke J. 2019;4(1):65–74.
52. Yamashita Y, Morimoto T, Toyota T, Shiomi H, Makiyama T,
Ono K, et al. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K
antagonist for venous thromboembolism: a systemic review and
meta-analysis. Thromb Res. 2018;166:37–42.
53. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK,
Deslandes B, et al. Venous thromboembolism risk and prophylaxis
in the acute hospital care setting (ENDORSE study): a multinational crosssectional study. Lancet. 2008;371:387–94.
54. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE,
Schulman S, et al. Prevention of VTE in orthopedic surgery
patients: antithrombotic therapy and prevention of thrombosis,
9th ed: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines. Chest. 2012;141:e278S-325S.
55. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit
JA, et al. Prevention of VTE in nonorthopedic surgical patients:
antithrombotic therapy and prevention of thrombosis, 9th ed:
American College of Chest Physicians Evidence- Based Clinical
Practice Guidelines. Chest. 2012;141:e227S – e277.
56. Fan Y, Jiang M, Gong D, Zou C. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of
randomized controlled trials. Sci Rep. 2016;6:25984.
57. Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, et al. Heparin
therapy reduces 28-day mortality in adult severe sepsis patients:
a systematic review and meta-analysis. Crit Care. 2014;18(5):563.
58. Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A,
Houston DS, et al. The efficacy and safety of heparin in patients
with sepsis: a systematic review and metaanalysis. Crit Care Med.
2015;43(3):511–8.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.

13

